Erlotinib antitumor activity in non-small cell lung cancer models is independent of HER1 and HER2 overexpression.

Abstract

BACKGROUND The human epidermal growth factor receptors HER1/EGFR and HER2 offer potential targets for treating non-small cell lung cancer (NSCLC). The antitumor efficacy of erlotinib (Tarceva, F. Hoffmann-La Roche, Ltd., Basel, Switzerland), a HER1/EGFR tyrosine-kinase inhibitor, was investigated in relation to HER1/EGFR and HER2 expression in five NSCLC… (More)

Topics

5 Figures and Tables

Cite this paper

@article{Friess2006ErlotinibAA, title={Erlotinib antitumor activity in non-small cell lung cancer models is independent of HER1 and HER2 overexpression.}, author={Thomas Friess and Werner V. Scheuer and M. J. Hasmann}, journal={Anticancer research}, year={2006}, volume={26 5A}, pages={3505-12} }